LHRH implant for prostate cancer to be discontinued

January 10, 2008

Bayer HealthCare Pharmaceuticals, Inc. said it will discontinue marketing of leuprolide acetate implant (Viadur), which is indicated for the treatment of advanced prostate cancer. Based on diminished market demand and growing manufacturing costs, the company has concluded that the product has limited long-term market viability. Bayer said the decision is not the result of safety or efficacy issues.

Bayer HealthCare Pharmaceuticals, Inc. said it will discontinue marketing of leuprolide acetate implant (Viadur), which is indicated for the treatment of advanced prostate cancer. Based on diminished market demand and growing manufacturing costs, the company has concluded that the product has limited long-term market viability. Bayer said the decision is not the result of safety or efficacy issues.

Bayer will fulfill orders until current supplies are depleted, expected by the end of April 2008. Alternative therapies are available for the palliative care of prostate cancer patients. Patients are being advised to discuss these options with their health care providers.